Loading…
← CockpitCompetitor Analysis › 300453.SZ Jiang Xi Sanxin Medtec Co Ltd Class AOpen in the cockpit ↗

Jiang Xi Sanxin Medtec Co Ltd Class A300453.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum leader 88
Mkt cap
$744M
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$9.33M
20-day average traded
Fwd P/E
16.2×
forward earnings
ROIC−WACC
+13.6 pp
WACC 5.9%
Hurdle
-14 pp
Req g minus delivered
Next earnings
124 days
22 Mar 2027
Close · CNYCN¥9.67
1D+0.3%
1W+2.1%
1M+4.4%
3M-3.5%
6M-3.0%
YTD+10.9%
1Y-1.6%
ATR %2.3%
52w lowhigh10.3% off high

What Jiang Xi Sanxin Medtec does

Employees: 2,297

Jiang Xi Sanxin Medtec at a glance

Size Jiang Xi Sanxin Medtec (300453.SZ) is a China Health Care company (Medical Specialties) with a market value of $744M, the 2749th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.67 on 18 Nov 2026.

Performance Over six months the shares fell 3.0%, against -16.3% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 12.1% over the last twelve months (peer median +10.0%); the operating margin is 18.4% (peer median 13.1%).

Valuation It trades at 16.2× forward earnings against a peer median of 19.9× (6th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 13.6 points above its cost of capital (5.9% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026300453.SZ 99Peer median 85
Six months, rebased to 100: Jiang Xi Sanxin Medtec against the median of its 20 peers (local-currency closes).

Jiang Xi Sanxin Medtec financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.78BCN¥1.63BCN¥1.49BCN¥1.29BCN¥1.33B
Revenue growth—+9%+15%-3%—
Gross profitCN¥712MCN¥541MCN¥489MCN¥421MCN¥420M
EBITDAn/aCN¥418MCN¥356MCN¥304MCN¥275M
Net incomeCN¥290MCN¥265MCN¥227MCN¥207MCN¥185M
Free cash flowCN¥174MCN¥231MCN¥181MCN¥58.7MCN¥195M
Capital expenditureCN¥253MCN¥242MCN¥218MCN¥287MCN¥211M
Total debtCN¥931MCN¥394MCN¥354MCN¥343MCN¥282M

Quarterly statements and history in the cockpit →

Jiang Xi Sanxin Medtec competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%-10%0%+10%603108002950INMD6008553013676881793004632190301122VREX1302CTKBMLABBBNX300622SETL6884107575300453.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Jiang Xi Sanxin Medtec is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×200×400×603108INMD301367688179688108300463301122VREX688410300453.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiang Xi Sanxin Medtec is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%603108INMD301367688179688108300463219013027575300453.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jiang Xi Sanxin Medtec is the large dot.

Jiang Xi Sanxin Medtec competitors and peer comparison

How Jiang Xi Sanxin Medtec compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiang Xi Sanxin Medtec against its 20 peers (data as of 18 Nov 2026)
Measure300453.SZPeer medianRank in peer set
1-month return+4.4%-8.5%6th highest of 21
6-month return-3.0%-16.3%8th highest of 21
Distance from 52-week high-10.3%-39.8%5th highest of 21
Revenue growth (TTM)+12.1%+10.0%11th highest of 21
Operating margin18.4%13.1%7th highest of 21
Forward P/E16.2×19.9×6th cheapest of 16
Growth the price implies (Req g, 7 yrs)-1.9%7.9%5th least demanding of 14
Growth delivered (Del g)+11.8%+15.5%5th lowest of 14
Hurdle (Req g minus delivered)-13.7 pp-9.8 pp6th least demanding of 14
ROIC minus cost of capital+13.6 pp-0.3 pp5th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%16.2×-1.9%+11.8%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%20.5×20.3%-0.2%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%n/an/an/a
InMode INMDUnited States$741M-8%+2%18%9.8×-10.8%+12.4%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%n/an/an/a
BMC Medical 301367.SZChina$737M-17%+37%17%18.7×-1.5%+15.6%
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%27.4×17.1%+24.2%
Sino Medical Sciences Technology 688108.SSChina$753M-41%+22%19%60.0×27.9%+9.9%
Maccura Biotechnology 300463.SZChina$756M-18%-1%-4%421.0×7.9%-10.2%
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%14.4×3.8%+105.8%
Caina Technology 301122.SZChina$721M+36%+61%0%55.4×n/an/a
Varex Imaging VREXUnited States$771M+79%+5%8%19.9×n/an/a
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%19.8×9.6%+15.5%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%n/an/an/a
Mesa Laboratories MLABUnited States$775M+33%+2%10%11.5×21.3%+13.2%
Beta Bionics BBNXUnited States$779M+42%+44%-73%n/an/an/a
Doctorglasses Chain 300622.SZChina$710M-22%+6%14%22.8×-3.4%+15.7%
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%n/an/an/a
SWS Hemodialysis Care 688410.SSChina$706M-11%+31%19%23.5×16.2%+25.9%
Japan Lifeline 7575.TJapan$703M+34%+6%19%14.5×-9.5%+2.9%
Shanghai INT Medical Instruments 1501.HKHong Kong$700M-25%+35%21%15.9×-3.3%+23.5%

Questions

Which companies are Jiang Xi Sanxin Medtec's closest peers?
The cockpit's peer set: Shanghai Runda Medical Technology (603108.SS), Allmed Medical Products (002950.SZ), InMode (INMD), Beijing Aerospace Changfeng (600855.SS), BMC Medical (301367.SZ), Shanghai Aladdin Biochemical Technology (688179.SS), Sino Medical Sciences Technology (688108.SS), Maccura Biotechnology (300463.SZ).
Is Jiang Xi Sanxin Medtec expensive compared with its peers?
On forward p/e it trades at 16.2× against a peer median of 19.9×, 6th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has Jiang Xi Sanxin Medtec stock performed?
Over six months to 18 Nov 2026 the shares returned -3.0% against -16.3% for the median peer; over one year -1.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.